NKMax Co Ltd
KOSDAQ:182400
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NKMax Co Ltd
Cash & Cash Equivalents
NKMax Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NKMax Co Ltd
KOSDAQ:182400
|
Cash & Cash Equivalents
₩980m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
-27%
|
|
|
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
₩1.1T
|
CAGR 3-Years
27%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash & Cash Equivalents
₩6.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash & Cash Equivalents
₩10.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
₩66.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash & Cash Equivalents
₩112B
|
CAGR 3-Years
65%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
NKMax Co Ltd
Glance View
NKMAX Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2015-10-23. The firm is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The firm distributes its products within domestic market and to overseas markets.
See Also
What is NKMax Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
980m
KRW
Based on the financial report for Dec 31, 2025, NKMax Co Ltd's Cash & Cash Equivalents amounts to 980m KRW.
What is NKMax Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
-27%
Over the last year, the Cash & Cash Equivalents growth was -68%. The average annual Cash & Cash Equivalents growth rates for NKMax Co Ltd have been -45% over the past three years , -42% over the past five years , and -27% over the past ten years .
